The Latest Cardiac and Vascular News
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection […]
VANCOUVER, British Columbia, Nov. 19, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended September 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance […]
VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 1,150,000 common shares of the Company (the “Options”) to […]
September 09, 2019 00:05 ET | Source: Novoheart Holdings Inc. Novoheart seeks to revolutionize human heart tissue engineering for disease modeling and drug discovery Peer-reviewed publications feature results from the completion of two research contracts between Novoheart and Pfizer Novoheart’s proprietary MyHeartTM Platform of […]
VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are […]
VANCOUVER, British Columbia, June 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) is pleased to announce that it has completed its previously announced acquisition (the “Acquisition”) of all of the shares of Xellera Therapeutics […]
VANCOUVER, British Columbia, June 17, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) announced the appointment of Joseph Leung (“Joseph”) as its new Chief Financial Officer (“CFO”) and Corporate Secretary. Joseph will be replacing Dr. Camie Chan, […]
Xellera Therapeutics Limited will accelerate the progression of Novoheart’s current business scope Significantly enhances Novoheart’s liquidity, gaining access to approximately C$22,500,000 cash VANCOUVER, British Columbia, May 28, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced […]
VANCOUVER, British Columbia, Oct. 31, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has entered into a service agreement with Xellera Therapeutics Limited, representing Phase […]
VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, announced today that it has appointed Bernard Fermini, Ph.D.as Chief Research & Development Officer. Dr. Fermini has been […]
